Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon vs sufentanil for postoperative pain and PONV in laparoscopic uterine surgery
ChiCTR2500107453Phase 4Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Feb 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial in postoperative pain and postoperative nausea and vomiting (PONV) comparing Anrikefon group with sufentanil group (2 arms). Primary endpoint: Incidence of postoperative nausea and vomiting within 24 hours. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
hsk21542sufentanil
03
Conditions
postoperative painpostoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2500107453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107453.